RecruitingNot ApplicableNCT05700318
Study Using the ShiraTronics Migraine Therapy System
A Pilot Study Assessing Preliminary Safety and Efficacy of The ShiraTronics Migraine Therapy System in Relieving, Interrupting, and Preventing Chronic Migraine
Sponsor
ShiraTronics
Enrollment
40 participants
Start Date
May 5, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this pilot study is to assess the preliminary safety and efficacy of the ShiraTronics Migraine Therapy System in prophylactic treatment of patients with refractory chronic migraine.
Eligibility
Min Age: 22 Years
Inclusion Criteria5
- Participants who are 22 years of age or older.
- History of migraine ≥ 12 months.
- Participants experiencing between 15 to 26 headache days per month, with at least 8 headache days (per month) with migraine phenotype presentation.
- Inadequate response to, unwilling, or contraindicated to Onabotulinumtoxin A and CGRP monoclonal antibodies therapy.
- Stable use of migraine medication.
Exclusion Criteria6
- Post-traumatic headache.
- Medication overuse headache.
- New daily persistent headache.
- Report experiencing unremitting, continuous headaches with no relief.
- Previously implanted neurostimulator to treat headache.
- History of cervical radiofrequency ablation or had any other intervention/device for migraine.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DEVICEneurostimulator
The ShiraTronics Migraine Therapy System
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05700318